Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
Top Cited Papers
- 29 September 2005
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 353 (13) , 1332-1341
- https://doi.org/10.1056/nejmoa050935
Abstract
In November 2001, the Food and Drug Administration (FDA) approved drotrecogin alfa (activated) (DrotAA) for adults who had severe sepsis and a high risk of death. The FDA required a study to evaluate the efficacy of DrotAA for adults who had severe sepsis and a low risk of death.Keywords
This publication has 17 references indexed in Scilit:
- Adult-population incidence of severe sepsis in Australian and New Zealand intensive care unitsIntensive Care Medicine, 2004
- EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care unitsIntensive Care Medicine, 2004
- Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsisCritical Care Medicine, 2003
- Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsisThrombosis and Haemostasis, 2003
- Assessing the Use of Activated Protein C in the Treatment of Severe SepsisNew England Journal of Medicine, 2002
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001
- Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working GroupPublished by American Medical Association (AMA) ,1997
- The Data and Safety Monitoring Board and Acquired immune deficiency syndrome (AIDS) clinical trialsControlled Clinical Trials, 1995
- Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe SepsisJAMA, 1995
- APACHE IICritical Care Medicine, 1985